Amphastar Pharmaceuticals (AMPH) Insider Trading & Ownership $24.41 -0.09 (-0.37%) As of 04:00 PM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Amphastar Pharmaceuticals (NASDAQ:AMPH) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage27.10%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)5Amount OfInsider Selling(Last 12 Months)$3.96 M Get AMPH Insider Trade Alerts Want to know when executives and insiders are buying or selling Amphastar Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address AMPH Insider Buying and Selling by Quarter Amphastar Pharmaceuticals Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails4/1/2025Floyd F PetersenDirectorSell500$28.38$14,190.00 3/4/2025William J PetersCFOSell4,231$27.54$116,521.74 12/12/2024Rong ZhouEVPSell7,000$44.42$310,940.00 12/9/2024Richard K PrinsDirectorSell10,000$43.77$437,700.00 11/12/2024Richard K PrinsDirectorSell5,000$48.80$244,000.00 11/12/2024Rong ZhouEVPSell6,893$48.88$336,929.84 11/6/2024William J PetersCFOSell7,426$52.05$386,523.30 11/6/2024Yakob LiawatidewiEVPSell5,214$52.05$271,388.70 9/5/2024Floyd F PetersenDirectorSell3,000$46.47$139,410.00 8/26/2024Rong ZhouEVPSell4,000$48.35$193,400.00 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 8/12/2024Richard K PrinsDirectorSell17,101$43.07$736,540.07 7/31/2024William J PetersCFOSell10,282$44.23$454,772.86 6/27/2024William J PetersCFOSell3,596$40.93$147,184.28 6/10/2024Floyd F PetersenDirectorSell3,000$41.40$124,200.00 6/3/2024Floyd F PetersenDirectorSell500$42.65$21,325.00 5/1/2024Floyd F PetersenDirectorSell500$41.67$20,835.00 (Data available from 1/1/2013 forward) AMPH Insider Trading Activity - Frequently Asked Questions Who is on Amphastar Pharmaceuticals's Insider Roster? The list of insiders at Amphastar Pharmaceuticals includes Diane G Gerst, Floyd F Petersen, Howard Lee, Jack Y Zhang, Mary Z Luo, Michael A Zasloff, Richard K Prins, Rong Zhou, William J Peters, and Yakob Liawatidewi. Learn more on insiders at AMPH. What percentage of Amphastar Pharmaceuticals stock is owned by insiders? 27.10% of Amphastar Pharmaceuticals stock is owned by insiders. Learn more on AMPH's insider holdings. Which Amphastar Pharmaceuticals insiders have been selling company stock? The following insiders have sold AMPH shares in the last 24 months: Floyd F Petersen ($711,895.00), Howard Lee ($750,888.58), Mary Z Luo ($15,048,002.66), Michael A Zasloff ($1,636,169.98), Richard K Prins ($2,219,480.07), Rong Zhou ($2,245,615.24), William J Peters ($7,098,715.23), and Yakob Liawatidewi ($1,802,382.78). How much insider selling is happening at Amphastar Pharmaceuticals? Insiders have sold a total of 602,968 Amphastar Pharmaceuticals shares in the last 24 months for a total of $31,513,149.54 sold. Amphastar Pharmaceuticals Key ExecutivesDr. Ziping Luo Ph.D. (Age 74)Chairman of the Board, Chief Scientist & COO Compensation: $1.36MDr. Yongfeng Zhang Ph.D. (Age 77)Co-Founder, President, CEO, Chief Scientific Officer & Director Compensation: $2MMr. William J. Peters M.B.A. (Age 56)CFO, Executive VP of Finance, Treasurer & Director Compensation: $1.21M2 recent tradesMr. Jacob Liawatidewi M.B.A. (Age 50)Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director Compensation: $880.1kMr. Rong Zhou M.S. (Age 65)Senior EVP of Production & EVP of Scientific Affairs Compensation: $962.3kMr. Dan Dischner M.B.A.Senior Vice President of Human Resources & Corporate CommunicationTony Marrs M.B.A.M.P.H., M.S., Executive VP of Regulatory Affairs & Clinical Operations More Insider Trading Tools from MarketBeat Related Companies Elanco Animal Health Insider Ownership Vaxcyte Insider Ownership Rhythm Pharmaceuticals Insider Ownership PTC Therapeutics Insider Ownership Avidity Biosciences Insider Ownership Arcellx Insider Ownership Ultragenyx Pharmaceutical Insider Ownership Zai Lab Insider Ownership Akero Therapeutics Insider Ownership Merus Insider Ownership Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 5 Mid-Cap Stocks Insiders Are Buying This YearInsider Buying in This Stock Reiterates Analysts Bullish OutlookBeware of BigBear.ai: Insiders Are Selling—Should You?XPO Buying $50 Million of Its Own Stock: Here's Why Top 3 Large Cap Stocks Insiders Bought in Q1: Buy, Sell, or Hold This page (NASDAQ:AMPH) was last updated on 4/30/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amphastar Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amphastar Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
